Resultados de la búsqueda

Piqueras-Flores J, Villacorta-Argüelles E, Galvin J, Climent-Payá V, Escobar-López LE, Amor-Salamanca A, Garcia-Hernandez S, Esmonde S, Martínez-Del Río J, Soto-Pérez M, Garcia-Pavia P, Ochoa JP. Intermediate-effect size p.Arg637Gln in FHOD3 increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers. J MED GENET (2024) 61:423-427

García-Hernández S, de la Higuera Romero L, Ochoa JP, McKenna WJ. Emerging Themes in Genetics of Hypertrophic Cardiomyopathy: Current Status and Clinical Application. Can J Cardiol (2024) S0828-282X:00023-0.
Link to the full text in Repisalud

Remior-Pérez P, Gómez-Molina M, García-Rodríguez D, Gallego-Delgado M, Mohamed-Salem L, de Haro-Del Moral J, Hernández-Terciado F, de Castro D, Eiros-Bachiller R, Dominguez F, Gonzalez-Lopez E, Villacorta E, Pascual-Figal DA, Garcia-Pavia P. Prevalence of cardiac amyloidosis among elderly patients with recent-onset atrial fibrillation. The PREVAL-ATTR study. Can J Cardiol (2024) S0828-282X:01028-6
Link to the full text in Repisalud

Peiró-Aventín B, Cabrera-Romero E, Mora-Ayestarán N, Domínguez F, González-López E, García-Pavía P. Safety and efficacy of diflunisal in transthyretin cardiac amyloidosis. Rev Esp Cardiol (2024) 77:426-428.
Link to the full text in Repisalud

Fernández-Cisnal A, Avanzas P, Filgueiras-Rama D, Garcia-Pavia P, Sanchis L, Sanchis J. ChatGPT-4 versus human assessment in cardiology peer review. Rev Esp Cardiol (2024) S1885-5857:00066-5.

Restrepo-Córdoba MA, Chmielewski P, Truszkowska G, Peña-Peña ML, Kubánek M, Krebsová A, Lopes LR, García-Ropero Á, Merlo M, Paldino A, Peters S, Jurcut R, Barriales-Villa R, Zorio E, Hazebroek M, Mogensen J, García-Pavía P. Pregnancy in women with dilated cardiomyopathy genetic variants. Rev Esp Cardiol (2024) (24):00128-2.
Link to the full text in Repisalud

García-Pavía P, Manuel García-Pinilla J, Lozano-Bahamonde A, Yun S, García-Quintana A, Gavira-Gómez JJ, Aibar-Arregui MÁ, Barge-Caballero G, Villota JN, Bernal L, Tarilonte P. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Rev Esp Cardiol (2024) S1885-5857:00240-8.
Link to the full text in Repisalud

Saturi G, De Frutos F, Sguazzotti M, Gonzalez-Lopez E, Nardi E, Domínguez F, Ponziani A, Cabrera E, Caponetti AG, Lozano S, Massa P, Cobo-Marcos M, Accietto A, Castro-Urda V, Giovannetti A, Toquero J, Gagliardi C, Gómez-Bueno M, Rios-Tamayo R, Biagini E, Segovia J, Galiè N, García-Pavía P, Longhi S. Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis. Heart (2024) 110:40-48

Yun S, Palladini G, Anderson LJ, Cariou E, Wang R, Angeli FS, Ebede B, Garcia-Pavia P. International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction. Amyloid (2024) 31:291-301

de Frutos F, Saturi G, Gonzalez-Lopez E, Sguazzotti M, Dominguez F, Ponziani A, Cabrera-Romero E, Caponetti AG, Lozano S, Massa P, Peiro-Aventin B, Accietto A, Mora-Ayestarán N, Giovannetti A, Castro-Urda V, Gagliardi C, Cobo-Marcos M, Rios-Tamayo R, Biagini E, Gomez-Bueno M, Galiè N, Segovia-Cubero J, Longhi S, Garcia-Pavia P. Incidence and predictors of sudden death in patients with cardiac amyloidosis. Amyloid (2024) 31:334-338
Link to the full text in Repisalud